236 related articles for article (PubMed ID: 27710140)
1. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
Douglas AP; Slavin MA
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140
[TBL] [Abstract][Full Text] [Related]
2. Complications of invasive mycoses in organ transplant recipients.
Samanta P; Singh N
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1195-1202. PubMed ID: 27690694
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).
Boğa C; Bolaman Z; Çağırgan S; Karadoğan İ; Özcan MA; Özkalemkaş F; Saba R; Sönmez M; Şenol E; Akan H; Akova M
Turk J Haematol; 2015 Jun; 32(2):100-17. PubMed ID: 26316478
[TBL] [Abstract][Full Text] [Related]
4. Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.
Ceesay MM; Kordasti S; Rufaie E; Lea N; Smith M; Wade J; Douiri A; Mufti GJ; Pagliuca A
J Infect; 2016 Sep; 73(3):280-8. PubMed ID: 27343564
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
Reslan Z; Lindsay J; Kerridge I; Gellatly R
Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
[TBL] [Abstract][Full Text] [Related]
6. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
8. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
10. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.
van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740
[TBL] [Abstract][Full Text] [Related]
11. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
[TBL] [Abstract][Full Text] [Related]
12. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough invasive fungal infections: Who is at risk?
Jenks JD; Cornely OA; Chen SC; Thompson GR; Hoenigl M
Mycoses; 2020 Oct; 63(10):1021-1032. PubMed ID: 32744334
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
15. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Sun Y; Hu J; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Transpl Infect Dis; 2021 Aug; 23(4):e13611. PubMed ID: 33825274
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
18. Approach to diagnostic evaluation and prevention of invasive fungal disease in patients prior to allogeneic hematopoietic stem cell transplant.
O'Keeffe JC; Singh N; Slavin MA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14197. PubMed ID: 37988269
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
Cornely OA; Ullmann AJ; Karthaus M
Blood; 2003 May; 101(9):3365-72. PubMed ID: 12393455
[TBL] [Abstract][Full Text] [Related]
20. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
